Indaptus Therapeutics’ (INDP) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Indaptus Therapeutics (NASDAQ:INDP) in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a $12.00 price objective on the stock. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q1 2024 earnings at ($0.57) EPS, Q2 2024 earnings at ($0.60) EPS, Q4 2024 earnings at ($0.34) EPS, FY2024 earnings at ($1.83) EPS, Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS and FY2025 earnings at ($1.44) EPS.

Indaptus Therapeutics Price Performance

Shares of NASDAQ:INDP opened at $2.66 on Monday. The business has a 50 day simple moving average of $2.13 and a two-hundred day simple moving average of $2.10. Indaptus Therapeutics has a 1 year low of $1.56 and a 1 year high of $4.08. The firm has a market capitalization of $22.71 million, a PE ratio of -1.45 and a beta of 1.28.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings data on Wednesday, March 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. Equities research analysts expect that Indaptus Therapeutics will post -1.73 EPS for the current fiscal year.

Institutional Investors Weigh In On Indaptus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INDP. Vanguard Group Inc. increased its position in shares of Indaptus Therapeutics by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 256,265 shares of the company’s stock worth $451,000 after acquiring an additional 5,517 shares during the period. Renaissance Technologies LLC bought a new position in Indaptus Therapeutics in the second quarter worth approximately $51,000. State Street Corp purchased a new position in Indaptus Therapeutics during the 1st quarter worth $78,000. Citadel Advisors LLC bought a new stake in Indaptus Therapeutics during the 4th quarter valued at $29,000. Finally, Northern Trust Corp purchased a new stake in shares of Indaptus Therapeutics in the 1st quarter worth $41,000. Institutional investors own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.